Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
Pratishtha Chatterjee(Edith Cowan University), Ralph N. Martins(Edith Cowan University), Nicholas J. Ashton(King's College London), Joel Simrén(University of Gothenburg), Kathryn Goozee(Edith Cowan University), Kaj Blennow(Sahlgrenska University Hospital), Hamid R. Sohrabi(Murdoch University), Steve Pedrini(Edith Cowan University), Eugene Hone(Edith Cowan University), Kevin Taddei(Edith Cowan University), Colin L. Masters(Mental Health Research Institute), Thomas K. Karikari(University of Pittsburgh), Victor L. Villemagne(The University of Melbourne), Prita R. Asih(Australian Alzheimer’s Research Foundation), Nicola J. Armstrong(The University of Sydney), Eugeen Vanmechelen(ADx NeuroSciences), Henrik Zetterberg(University of Wisconsin–Madison), Vincent Doré(Australian e-Health Research Centre), Abhay Kumar Singh(Macquarie University), Michelle Tegg(Edith Cowan University)
Cited by 238
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k